+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Oncology/Cancer Drugs Market Trend & Segmentation, by Drug Class Type, by Indication, by Region; Trend Analysis, Competitive Market Share & Forecast, 2016-26

  • ID: 4997121
  • Report
  • January 2020
  • Region: Global
  • 125 pages
  • Blueweave Consulting & Research Pvt Ltd
1 of 3
The global market for Oncology/Cancer Drugs predicted to expand at a 7.2% CAGR. An increase in the incidence of cancer cases worldwide and a significant increase in government spending on healthcare services facilitate growth in the global market for oncology/cancer drugs. Deadly effects of using cancer drugs, is hampering the development of the market. The increasing burden of cancer is due to several factors, including population growth and aging, as well as the changing prevalence of specific cancer causes linked to social and economic development. These factors especially true in fast-growing economies, where there is a change from poverty-related cancers and infections to lifestyle-related cancers and directly drives demand for oncology drugs on the global market with significant growth speed. High costs associated with the development of new medications, coupled with the threat of failure and adverse effects anticipated related to cancer drug therapies, will restrict the market growth.

In contrast, a high potential of emerging economies and an increase in the number of pipeline products are expected to provide new opportunities for market players in the future.

Chemotherapy drugs hold the largest market share of oncology/cancer drugs during the forecast period

As a result of their killing effect on cancer cells, demand for chemotherapy drugs has risen at a stellar speed. Some of the main categories of the global market for oncology/cancer drugs, based on indication, include cervical cancer, kidney cancer, breast cancer, and prostate cancer. The availability of progressive treatment facilities, intensifying government initiatives to encourage research to find a cure to the mounting number of cancer cases, and increasing healthcare spending are motivating the development of the chemotherapy market in the global region. North America was the leading contributor to the worldwide market in 2019. However, during the forecast period, Asia-Pacific is expected to grow due to an increase in disposable income, a rise in research, development and innovation activities, and an increase in awareness of various cancers.

Targeted therapy segment predicted to be the significant market-driven of oncology/cancer drugs across the globe

During the forecast period, the targeted therapy segment had the largest market share of oncology/cancer drugs. Because of the ability of targeted therapies to kill only malignant cells, the increased efficacy and survival rates associated with their use. Immunotherapy drugs are widely acknowledged as an ideal form of treatment as these drugs are potentially harmless to the rest of the body's living cells, making them less toxic than other cancer therapy methods. Additionally, ongoing R&D efforts to design and develop new immunotherapy to treat different types of cancer serve as a critical factor in the oncology/cancer drug market's growth.

Oncology/cancer drugs: Competitive Landscape

The major market players in the oncology/cancer drugs are focusing on explaining their portfolio of services in the global market. Such as AbbVie Inc., Astellas Pharma Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Celgene Corporation, F. Hoffmann-La Roche Ltd., Johnson & Johnson (Janssen Global Services, LLC,), Merck & Co., Inc., Novartis AG, Pfizer Inc., and other prominent players.

The in-depth analysis of the report provides the growth potential, upcoming trends, and statistics of Oncology/cancer drugs market size & forecast. The report promises to provide state-of-the-art technology of Oncology/cancer drugs and industry insights which help decision-makers to take sound strategic decisions. Furthermore, the report also analyzes the market drivers and challenges and competitive analysis of the market.
Note: Product cover images may vary from those shown
2 of 3
1. Research Framework
1.1. Research Objective
1.2. Product Overview
1.3. Market Segmentation

2. Research Methodology
2.1. Qualitative Research
2.1.1. Primary & Secondary Sources
2.2. Quantitative Research
2.2.1. Primary & Secondary Sources
2.3. Breakdown of Primary Research Respondents, By Region
2.3.1. Secondary Research
2.3.2. Primary Research
2.4. Breakdown of Primary Research Respondents
2.5. Market Size Estimation
2.6. Assumption for the Study
2.7. Market Breakdown & Data Triangulation

3. Executive Summary

4. Global Oncology/Cancer Drugs Insights
4.1. Industry Value Chain Analysis
4.2. DROC Analysis
4.2.1. Growth Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Technological Landscape
4.4. Regulatory Framework
4.5. Company market share analysis, 2019
4.6. Porter’s Five forces analysis
4.6.1. Bargaining Power of Suppliers
4.6.2. Bargaining Power of Buyers
4.6.3. Threat of New Entrants
4.6.4. Threat of Substitutes
4.6.5. Intensity of Rivalry

5. Global Oncology/Cancer Drugs Market Overview
5.1. Market Size & Forecast 2016-2026
5.1.1. By Value (USD)
5.2. Market Share & Forecast
5.2.1. By Drug Class Type
5.2.1.1. Chemotherapy
5.2.1.2. Targeted Therapy
5.2.1.3. Immunotherapy (Biologic Therapy)
5.2.1.4. Hormonal Therapy
5.2.2. By Indication
5.2.2.1. Lung Cancer
5.2.2.2. Stomach Cancer
5.2.2.3. Colorectal Cancer
5.2.2.4. Breast Cancer
5.2.2.5. Prostate Cancer
5.2.2.6. Liver Cancer
5.2.2.7. Esophagus Cancer
5.2.2.8. Cervical Cancer
5.2.2.9. Kidney Cancer
5.2.2.10. Bladder Cancer
5.2.2.11. Other Cancer
5.2.3. By Region
5.2.3.1. North America
5.2.3.2. Europe
5.2.3.3. Asia Pacific
5.2.3.4. Latin America
5.2.3.5. Middle East & Africa

6. North America Oncology/Cancer Drugs Market
6.1. Market Size & Forecast 2016-2026
6.1.1. By Value (USD)
6.2. Market estimates & forecast
6.2.1. By Class Type
6.2.2. By Indication
6.2.3. By Country
6.2.3.1. U.S
6.2.3.2. Canada

7. Europe Oncology/Cancer Drugs Market
7.1. Market Size & Forecast 2016-2026
7.1.1. By Value (USD)
7.2. Market estimates & forecast
7.2.1. By Class Type
7.2.2. By Indication
7.2.3. By Country
7.2.3.1. Germany
7.2.3.2. U.K
7.2.3.3. France
7.2.3.4. Italy
7.2.3.5. Rest of Europe

8. Asia Pacific Oncology/Cancer Drugs Market
8.1. Market Size & Forecast 2016-2026
8.1.1. By Value (USD)
8.2. Market estimates & forecast
8.2.1. By Class Type
8.2.2. By Indication
8.2.3. By Country
8.2.3.1. China
8.2.3.2. India
8.2.3.3. Japan
8.2.3.4. South Korea
8.2.3.5. Rest of APAC

9. Latin America Oncology/Cancer Drugs Market
9.1. Market Size & Forecast 2016-2026
9.1.1. By Value (USD)
9.2. Market estimates & forecast
9.2.1. By Class Type
9.2.2. By Indication
9.2.3. By Country
9.2.3.1. Brazil
9.2.3.2. Mexico
9.2.3.3. Argentina
9.2.3.4. Rest of Latin America

10. Middle East & Africa Oncology/Cancer Drugs Market
10.1. Market Size & Forecast 2016-2026
10.1.1. By Value (USD)
10.2. Market estimates & forecast
10.2.1. By Class Type
10.2.2. By Indication
10.2.3. By Country
10.2.3.1. Saudi Arabia
10.2.3.2. UAE
10.2.3.3. South Africa
10.2.3.4. Rest of MEA

11. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook)*
11.1. AbbVie Inc.
11.2. Astellas Pharma, Inc.
11.3. AstraZeneca PLC
11.4. Bristol-Myers Squibb Company
11.5. Celgene Corporation
11.6. F. Hoffmann-La Roche Ltd.
11.7. Johnson & Johnson (Janssen Global Services, LLC,)
11.8. Merck & Co., Inc.
11.9. Novartis AG
11.10. Pfizer Inc.
11.11. Other Prominent Players
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

Adroll
adroll